ZD6474 – clinical experience to date

por Heymach, J V
Publicado 2005

EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung...

por Heymach, J. V., Lockwood, S. J., Herbst, R. S., Johnson, B. E., Ryan, A. J.
Publicado 2014

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors

por Morgillo, F, Cascone, T, D'Aiuto, E, Martinelli, E, Troiani, T, Saintigny, P, De Palma, R, Heymach, J V, Berrino, L, Tuccillo, C, Ciardiello, F
Publicado 2011

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation...

por Garon, E.B., Reck, M., Nishio, K., Heymach, J.V., Nishio, M., Novello, S., Paz-Ares, L., Popat, S., Aix, S. Ponce, Graham, H., Butts, B.D., Visseren-Grul, C., Nakagawa, K.
Publicado 2023

Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma

por Zurita, A J, Gagnon, R C, Liu, Y, Tran, H T, Figlin, R A, Hutson, T E, D'Amelio Jr, A M, Sternberg, C N, Pandite, L N, Heymach, J V
Publicado 2017

Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma

por Bhatt, R S, Zurita, A J, O'Neill, A, Norden-Zfoni, A, Zhang, L, Wu, H K, Wen, P Y, George, D, Sukhatme, V P, Atkins, M B, Heymach, J V
Publicado 2011

1736P Elevated AXL expression following SARS-CoV-2 infection in non-small cell lung cancer

por Ramkumar, K., Stewart, C.A., Gay, C., Cardnell, R., Diao, L., Wang, Q., Shen, L., Xi, Y., Kundu, S., Della Corte, C., Gibbons, D., Wang, J., Heymach, J.V., Byers, L.A.
Publicado 2020

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours

por Zurita, A J, Khajavi, M, Wu, H-K, Tye, L, Huang, X, Kulke, M H, Lenz, H-J, Meropol, N J, Carley, W, DePrimo, S E, Lin, E, Wang, X, Harmon, C S, Heymach, J V
Publicado 2015

1745P SARS-CoV-2 infects metabolically-primed epithelial cells in lung cancer models

por Cargill, K.R., Stewart, C.A., Gay, C., Ramkumar, K., Cardnell, R., Nilsson, M., Heeke, S., Park, E.M., Diao, L., Wang, Q., Shen, L., Le, X., Xi, Y., Kundu, K., Gibbons, D., Wang, J., Heymach, J.V., Byers, L.A.
Publicado 2020

1735P SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2, in lung cancer models

por Stewart, C.A., Gay, C., Ramkumar, K., Cargill, K.R., Cardnell, R., Nilsson, M., Heeke, S., Park, E.M., Kundu, S., Diao, L., Wang, Q., Shen, L., Xi, Y., Della Corte, C.M., Kundu, K., Gibbons, D.L., Wang, J., Heymach, J.V., Byers, L.A.
Publicado 2020

Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study

por Cascone, T., Sacks, R.L., Subbiah, I.M., Drobnitzky, N., Piha-Paul, S.A., Hong, D.S., Hess, K.R., Amini, B., Bhatt, T., Fu, S., Naing, A., Janku, F., Karp, D., Falchook, G.S., Conley, A.P., Sherman, S.I., Meric-Bernstam, F., Ryan, A.J., Heymach, J.V., Subbiah, V.
Publicado 2021

Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50%

por Gainor, J. F., Rizvi, H., Aguilar, E. Jimenez, Skoulidis, F., Yeap, B. Y., Naidoo, J., Khosrowjerdi, S., Mooradian, M., Lydon, C., Illei, P., Zhang, J., Peterson, R., Ricciuti, B., Nishino, M., Zhang, J., Roth, J. A., Grishman, J., Anderson, D., Little, B. P., Carter, B. W., Arbour, K., Sauter, J. L., Mino-Kenudson, M., Heymach, J. V., Digumarthy, S., Shaw, A. T., Awad, M. M., Hellmann, M. D.
Publicado 2019